Earlier this year, the U.K. government announced £82.6 million ($102.2 million) in research funding for artificial intelligence (AI) companies engaged in developing solutions that accelerate…
Over the past several years, Medical Affairs has evolved from a largely supportive, reactive function into a primary strategic pillar. In 2026, proving the value…
As the cost of developing new therapies continues to rise, pharma executives must turn to technologies that drive better insights into de-risked investments and produce…
While AI in the pharma cold chain promises exciting possibilities, achieving these benefits is not a sprint but a marathon. The journey towards fully integrating…
Adverse event (AE) case intake in Life Sciences is crying out for disruption by AI. And now, at last, Generative AI and Large Language Models…
Smart automation promises to transform life sciences research and development operations, and streamline pharma companies’ path to market while enhancing patient safety. But how far…
Did you know that it takes approximately seven years to develop and bring a new drug to market? However, this time can be significantly reduced…
The breakneck pace of digital transformation spurred by COVID-19 continued to reshape the life sciences landscape in 2023. Rather than a single watershed moment, this…
At the heart of Genomics England, we nurture a vision: a world where everyone benefits from genomic healthcare. This aspiration is expressed in supporting the…
The last decade has brought about many developments to genomics, stem cell research, cancer therapies and immunotherapy – to name just a few areas. Hand…
